Eli Lilly's new drug outperforms its predecessor in weight loss, the weight-loss drug market is expected to surge, Johnson & ...

Undeterred by domestic regulatory concerns, Hims & Hers is actively executing its global strategy. On December 10, the company launched its comprehensive weight-loss program in the United Kingdom, ...

With all of this in mind, let's check out my top 10 stocks to buy for 2026. They offer you a balanced blend of ...

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...